Drug
Levilimab
Levilimab is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (100.0%)
Trials by Status
completed150%
active_not_recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
active_not_recruitingphase_3
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
NCT05800327
completedphase_3
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
NCT04397562
Clinical Trials (2)
Showing 2 of 2 trials
NCT05800327Phase 3
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
NCT04397562Phase 3
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2